ACH
FDMT icon

ArrowMark Colorado Holdings’s 4D Molecular Therapeutics FDMT Stock Holding History

ArrowMark Colorado Holdings’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.89M Sell
202,864
-282,525
-58% -$2.46M 0.05% 221
2025
Q4 		$3.64M Sell
485,389
-18,726
-4% -$190K 0.08% 213
2025
Q3 		$4.38M Sell
504,115
-10,499
-2% -$62.7K 0.08% 200
2025
Q2 		$1.91M Sell
514,614
-12,656
-2% -$44.5K 0.03% 231
2025
Q1 		$1.7M Sell
527,270
-267,328
-34% -$1.26M 0.03% 233
2024
Q4 		$4.43M Sell
794,598
-8,892
-1% -$69.8K 0.06% 199
2024
Q3 		$8.69M Sell
803,490
-46,711
-5% -$775K 0.11% 151
2024
Q2 		$17.8M Sell
850,201
-228,124
-21% -$5.72M 0.21% 97
2024
Q1 		$34.4M Sell
1,078,325
-123,115
-10% -$3.14M 0.39% 71
2023
Q4 		$24.3M Buy
1,201,440
+116,719
+11% +$1.54M 0.27% 91
2023
Q3 		$13.8M Buy
1,084,721
+53,323
+5% +$892K 0.17% 112
2023
Q2 		$18.6M Sell
1,031,398
-1,321
-0.1% -$24.3K 0.2% 101
2023
Q1 		$17.8M Buy
1,032,719
+50,520
+5% +$982K 0.2% 102
2022
Q4 		$21.8M Sell
982,199
-547,759
-36% -$8.46M 0.26% 88
2022
Q3 		$12.3M Buy
1,529,958
+105,644
+7% +$957K 0.15% 127
2022
Q2 		$9.94M Buy
1,424,314
+278,729
+24% +$2.71M 0.11% 161
2022
Q1 		$17.3M Buy
1,145,585
+34,006
+3% +$534K 0.15% 131
2021
Q4 		$24.4M Buy
1,111,579
+108,132
+11% +$2.65M 0.2% 111
2021
Q3 		$27.1M Sell
1,003,447
-26,450
-3% -$754K 0.21% 112
2021
Q2 		$24.8M Sell
1,029,897
-18,292
-2% -$560K 0.19% 118
2021
Q1 		$45.5M Sell
1,048,189
-15,555
-1% -$689K 0.34% 80
2020
Q4 		$44.1M Buy
+1,063,744
New +$43.9M 0.34% 84

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ArrowMark Colorado Holdings's FDMT Position: Q1 2026 in Review

ArrowMark Colorado Holdings reduced its 4D Molecular Therapeutics (FDMT) stake by 58% in Q1 2026, selling an estimated $2.46M and leaving 202,864 shares worth $1.89M. The position accounts for 0.05% of the portfolio, ranked #221.

ArrowMark Colorado Holdings first reported a position in FDMT in Q4 2020 and has held it in 22 quarters since. The position peaked at $45.5M in Q1 2021. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • ArrowMark Colorado Holdings held 202,864 shares of 4D Molecular Therapeutics worth $1.89M as of Q1 2026.
  • ArrowMark Colorado Holdings sold 282,525 4D Molecular Therapeutics shares in Q1 2026, an estimated $2.46M.
  • 4D Molecular Therapeutics made up 0.05% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #221 holding.
  • ArrowMark Colorado Holdings first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • ArrowMark Colorado Holdings's 4D Molecular Therapeutics position peaked at $45.5M in Q1 2021.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.